Gender differences in Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 8, 2007, Pages 819-824

  Haaxma, Charlotte A ^a   Bloem, Bastiaan R ^a   Borm, George F ^a   Oyen, Wim J G ^a   Leenders, Klaus L ^b   Eshuis, Silvia ^b   Booij, Jan ^c   Dluzen, Dean E ^d   Horstink, Martin W I M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; LEVODOPA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGE OF ONSET; AGED; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOTOR SKILLS DISORDERS; PARKINSON DISEASE; PHENOTYPE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34547645967     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.103788     Document Type: Article

References (40)

1. Van Den Eeden SK, Tanner CM, Berstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicily. Am J Epidemiol 2003;157:1015-22.
2. de Lau LM, Giesbergen PC, de Rijk MC, et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240-4.
3. Wooten GF, Currie LJ, Bovbjerg VE, et al. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004;75:637-9.
4. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ 2000;321:21-2.
5. Claveria LE, Duarte J, Sevillano MD, et al. Prevalence of Parkinson's disease in Cantalejo, Spain: a door-to-door survey. Mov Disord 2002;17:242-9.
6. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003;18:267-74.
7. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31.
8. Lyons KE, Hubble JP, Tröster AI, et al. Gender differences in Parkinson's disease. Clin Neuropharmacol 1998;21:118-21.
9. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease. Arch Neurol 2005;62:601-5.
10. Scott B, Borgman A, Engler H, et al. Gender differences in Parkinson's disease symptom profile. Acta Neurol Scand 2000;102:37-43.
11. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997;767:340-4.
12. Goo X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385-94.
13. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003;110:1215-24.
14. Daria KP, Murray HE, Pillai AV, et al. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport 2003;14:47-50.
15. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005;65:383-90.
16. Currie LJ, Harrison MB, Trugman JM, et al. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886-8.
17. Ascherio A, Chen H, Schwarzschild MA, et al. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003;60:790-5.
18. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol 1999;22:93-7.
19. Blanchet PJ, Fang J, Hyland K, et al. Short-term effects of high-dose 17[beta]-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999;53:91-5.
20. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-7.
21. Rocca WA, Grossardt BR, Bower JH, et al. The Mayo Clinic Cohort study of oophorectomy and aging: results for parkinsonism and Parkinson's disease. Presented at the 57th annual meeting of the American Academy of Neurology, April 9-16, 2005, Miami Beach, Florida, USA.
22. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
23. 123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001;41:275-84.
24. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27:867-9.
25. Laakso A, Vilkman H, Bergman J, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 2002;52:759-63.
26. Pohjalainen T, Rinne JO, Nagren K, et al. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 1998;155:768-73.
27. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603-6.
28. Morissette M, Di Paolo T. Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 1993;58:16-22.
29. Rivest R, Falardeau P, Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 1995;692:269-72.
30. Morissette M, Di Paolo T. Effect of chronic estradiol and progesterone treatments on ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993;60:1876-83.
31. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;17:6853-61.
32. Martignoni E, Nappi RE, Citterio A, et al. Reproductive life milestones in women with Parkinson's disease. Funct Neurol 2003;18:211-17.
33. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004;11:2010-14.
34. 123I] beta-CIT SPECT. J Neural Transm 2000;107:543-52.
35. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
36. Pirker W, Holler I, Gerschlager W, et al. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18:1266-72.
37. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-82.
38. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
39. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-15.
40. Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-8.